Vertex Pharmaceuticals (0QZU) Share Forecast & Price Target
0QZU Analyst Ratings
Strong Buy
22Buy3Hold0Sell
Based on 25 analysts giving stock ratings to Vertex Pharmaceuticals in the past 3 months
0QZU Stock 12 Month Forecast
Average Price Target
$589.50▲(5.17% Upside)Based on 25 Wall Street analysts offering 12 month price targets for Vertex Pharmaceuticals in the last 3 months. The average price target is $589.50 with a high forecast of $667.00 and a low forecast of $442.00. The average price target represents a 5.17% change from the last price of $560.54.
Past 12 Months12 Month ForecastDec2025Sep2026
High$667.00
Average$589.50
Low$442.00
Highest Price TargetHighest$667.00Average Price Target$589.50Lowest Price TargetLowest$442.00
Detailed List of Analyst Forecasts
Analyst Type
Ranks
Analyst Rating
Upside/ Downside
Action
| Price Target | Follow | Article | ||||||
|---|---|---|---|---|---|---|---|---|
| Geoff Meacham | Citi | $585 | buy | 4.36%Upside | Reiterated | 10/27/26 | ||
| David Risinger | Leerink Partners | ― | buy | ― | Reiterated | 10/27/26 | ||
| Michael Yee | UBS | $615 | buy | 9.72%Upside | Assigned | 10/26/26 | ||
| Tazeen Ahmad | Bank of America Securities | $667 | buy | 18.99%Upside | Reiterated | 10/26/26 | ||
| Andrew Fein | H.C. Wainwright | $641 | buy | 14.35%Upside | Reiterated | 10/26/26 | ||
| Phil Nadeau | TD Cowen | $550 | buy | -1.88%Downside | Assigned | 10/26/26 | ||
| Louise Chen | Scotiabank | $558 | buy | -0.45%Downside | Reiterated | 10/26/26 | ||
| Carter Gould | Cantor Fitzgerald | $595 | buy | 6.15%Upside | Reiterated | 10/25/26 | ||
| Salveen Richter | Goldman Sachs | $653→$654 | buy | 16.67%Upside | Reiterated | 10/25/26 | ||
| Mohit Bansal | Wells Fargo | $550 | buy | -1.88%Downside | Reiterated | 10/15/26 | ||
| Evan Seigerman | BMO Capital | $600 | buy | 7.04%Upside | Reiterated | 10/12/26 | ||
| Brian Abrahams | RBC Capital | $570→$576 | buy | 2.76%Upside | Reiterated | 10/08/26 | ||
| Terence Flynn | Morgan Stanley | $665 | buy | 18.64%Upside | Assigned | 10/07/26 | ||
| Jeffrey Walch | Bernstein | $608 | buy | 8.47%Upside | Reiterated | 09/25/26 | ||
| Eliana Merle | Barclays | $617 | buy | 10.07%Upside | Reiterated | 09/23/26 |
| Price Target | Follow | Article | ||||||
|---|---|---|---|---|---|---|---|---|
| Geoff Meacham | 10/27/26 | $585 | buy | 4.36%Upside | Reiterated | Citi | ||
| David Risinger | 10/27/26 | ― | buy | ― | Reiterated | Leerink Partners | ||
| Michael Yee | 10/26/26 | $615 | buy | 9.72%Upside | Assigned | UBS | ||
| Tazeen Ahmad | 10/26/26 | $667 | buy | 18.99%Upside | Reiterated | Bank of America Securities | ||
| Andrew Fein | 10/26/26 | $641 | buy | 14.35%Upside | Reiterated | H.C. Wainwright | ||
| Phil Nadeau | 10/26/26 | $550 | buy | -1.88%Downside | Assigned | TD Cowen | ||
| Louise Chen | 10/26/26 | $558 | buy | -0.45%Downside | Reiterated | Scotiabank | ||
| Carter Gould | 10/25/26 | $595 | buy | 6.15%Upside | Reiterated | Cantor Fitzgerald | ||
| Salveen Richter | 10/25/26 | $653→$654 | buy | 16.67%Upside | Reiterated | Goldman Sachs | ||
| Mohit Bansal | 10/15/26 | $550 | buy | -1.88%Downside | Reiterated | Wells Fargo | ||
| Evan Seigerman | 10/12/26 | $600 | buy | 7.04%Upside | Reiterated | BMO Capital | ||
| Brian Abrahams | 10/08/26 | $570→$576 | buy | 2.76%Upside | Reiterated | RBC Capital | ||
| Terence Flynn | 10/07/26 | $665 | buy | 18.64%Upside | Assigned | Morgan Stanley | ||
| Jeffrey Walch | 09/25/26 | $608 | buy | 8.47%Upside | Reiterated | Bernstein | ||
| Eliana Merle | 09/23/26 | $617 | buy | 10.07%Upside | Reiterated | Barclays |
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
Best Analysts Covering Vertex Pharmaceuticals
3 Months
Success Rate26/35 ratings generated profit
74%
Average Return
+7.84%
Copying Mohit Bansal's trades and holding each position for 3 Months would result in 74.29% of your transactions generating a profit, with an average return of +7.84% per trade.
1 Year
Success Rate20/25 ratings generated profit
80%
Average Return
+12.98%
Copying Salveen Richter's trades and holding each position for 1 Year would result in 80.00% of your transactions generating a profit, with an average return of +12.98% per trade.
2 Years
Success Rate19/19 ratings generated profit
100%
Average Return
+18.41%
Copying Tazeen Ahmad's trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +18.41% per trade.
0QZU Analyst Recommendation Trends
| Rating | May 26 | Jun 26 | Jul 26 | Aug 26 | Sep 26 |
|---|---|---|---|---|---|
| Strong Buy | 0 | 0 | 0 | 0 | 0 |
| Buy | 33 | 50 | 59 | 70 | 62 |
| Hold | 9 | 9 | 9 | 9 | 6 |
| Sell | 0 | 1 | 1 | 1 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 |
| total | 42 | 60 | 69 | 80 | 68 |
In the current month, 0QZU has received 62 Buy Ratings, 6 Hold Ratings, and 0 Sell Ratings. 0QZU average Analyst price target in the past 3 months is 589.50.
0QZU Financial Forecast
High$5.25
Consensus$4.82
Low$3.68
0QZU Earnings Forecast
Next quarter’s earnings estimate for 0QZU is $4.82 with a range of $3.68 to $5.25. The previous quarter’s EPS was $4.73. Its overall industry beat the EPS estimate 57.80% of the time in the past 12 months.
High$3.5B
Consensus$3.42B
Low$3.33B
0QZU Sales Forecast
Next quarter’s sales forecast for 0QZU is $3.42B with a range of $3.33B to $3.50B. The previous quarter’s sales results were $3.34B. Its overall industry beat sales estimates 50.04% of the time in the past 12 months.
0QZU Stock Forecast FAQ
What is GB:0QZU’s average 12-month price target, according to analysts?
Based on analyst ratings, Vertex Pharmaceuticals’s 12-month average price target is $589.50.
What is GB:0QZU’s upside potential, based on the analysts’ average price target?
Vertex Pharmaceuticals has 5.17% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is Vertex Pharmaceuticals a Buy, Sell or Hold?
Vertex Pharmaceuticals has a consensus rating of Strong Buy, which is based on 22 buy ratings, 3 hold ratings and 0 sell ratings.
What is Vertex Pharmaceuticals’s share price target?
The average share price target for Vertex Pharmaceuticals is $589.50. This is based on 25 Wall Street analysts’ 12-month price targets, issued in the past 3 months. The highest analyst share price target is $667.00, and the lowest forecast is $442.00. The average share price target represents a 5.17% increase from the current price of $560.54.
What do analysts say about Vertex Pharmaceuticals?
Vertex Pharmaceuticals’s analyst rating consensus is a Strong Buy. This is based on the ratings of 25 Wall Street analysts.
How can I buy shares of Vertex Pharmaceuticals?
To buy shares of GB:0QZU, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.